A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients with Multiple System Atrophy

Multiple System Atrophy

The primary efficacy endpoint (TEV-56286 versus placebo, change from baseline to week 48) is as follows: • modified UMSARS part I (excluding item 11, item scoring rescaled 0-3)

The Secondary efficacy endpoints (TEV-56286 versus placebo, change from baseline to week 48) are as follows: • total UMSARS score (part I and part II combined) • UMSARS part I score • CGI-S • MSA-QoL, Safety endpoints include the following: 1. number (%) of participants per adverse events, Safety endpoints include the following: 2. number (%) of patients who withdraw from the study due to an adverse event, Safety endpoints include the following: 4. number (%) of patients with potentially clinically significant vital sign values, Safety endpoints include the following: 5. number (%) of patients with potentially clinically significant laboratory test values (hematology and chemistry), Safety endpoints include the following: 6. number (%) of patients with potentially clinically significant changes in 12-lead ECG measurements, Safety endpoints include the following: 3.number (%) of patients who withdraw from treatment due to an adverse event

No related papers found yet.

France, Germany, Italy, Spain